Lu Gan
Company: Scholar Rock
Job title: VP, Head of Medical Research/Oncology Franchise
Seminars:
SRK-181, A Latent TGF-β Inhibitor: Safety & Efficacy Results From the Dose Escalation Portion of a Phase I Trial (DRAGON Trial) in Patients with Advanced Solid Tumors 4:20 pm
Exploring the SRK-181 mechanism of action and study design Navigating dose escalation and safety data to determine how high the dose and what the safety profile of the therapeutic looks likeRead more
day: Day One